Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
Questcor fourth quarter net sales increase to $75.5 million

Questcor fourth quarter net sales increase to $75.5 million

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

Patients with PsA may benefit from new medications and surgeries

Patients with PsA may benefit from new medications and surgeries

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

TNF inhibitors may minimally increase risk of serious infections

TNF inhibitors may minimally increase risk of serious infections

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

IFPA event to raise awareness of psoriasis on Oct. 29

IFPA event to raise awareness of psoriasis on Oct. 29

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Study finds 22% of psoriasis patients with symptoms of psoriatic arthritis

Study finds 22% of psoriasis patients with symptoms of psoriatic arthritis

Nearly one in four people with psoriasis may have undiagnosed psoriatic arthritis

Nearly one in four people with psoriasis may have undiagnosed psoriatic arthritis

ACR celebrates World Arthritis Day with the theme 'Move to Improve'

ACR celebrates World Arthritis Day with the theme 'Move to Improve'

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Janssen Biotech receives FDA approval for Remicade to treat UC in children

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers file lawsuit against Abbott in Texas state court

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA